Diabetes drugs Avandia and Actos double the risk of heart failure in patients, according to a report in the August issue of Diabetes Care.
The risk occurs at even the lowest dose, according to lead author Dr. Sonal Singh, of Wake Forest University School of Medicine.
The report comes on the heels of a recent U.S. government review that found Avandia’s heart risks are far higher than Actos’. As a result of this government report, an advisory panel hearing today is expected to examine whether Avandia’s cardiovascular risks warrant a stronger warning label.